AC
MIST icon

Aaron Cowen’s Milestone Pharmaceuticals MIST Stock Holding History

Aaron Cowen’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-851,291
Closed -$5.58M – 99
2021
Q4 		$5.58M Hold
851,291
– – 0.11% 71
2021
Q3 		$4.86M Hold
851,291
– – 0.08% 80
2021
Q2 		$4.68M Hold
851,291
– – 0.07% 93
2021
Q1 		$4.93M Hold
851,291
– – 0.07% 85
2020
Q4 		$5.7M Buy
+851,291
New +$5.7M 0.08% 73

Other funds holding MIST

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Aaron Cowen's MIST Position: Q1 2022 in Review

Aaron Cowen sold out of Milestone Pharmaceuticals (MIST) in Q1 2022, closing a stake of 851,291 shares — an estimated $5.58M sold.

Aaron Cowen first reported a position in MIST in Q4 2020 and held it in 5 quarters. The position peaked at $5.7M in Q4 2020. 28 funds tracked by Wall St. Rank hold MIST as of Q1 2022.

  • Aaron Cowen reported no remaining Milestone Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Aaron Cowen sold 851,291 Milestone Pharmaceuticals shares in Q1 2022, an estimated $5.58M.
  • Aaron Cowen first reported a position in Milestone Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Aaron Cowen's Milestone Pharmaceuticals position peaked at $5.7M in Q4 2020.
  • 28 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2022.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.